

Amendments to the Claims:

This listing of claims replaces all prior versions of the claims in the application:

1.-35. (Canceled)

36. (Currently Amended) An isolated hyperimmune serum-reactive antigen comprising an amino acid sequence consisting of SEQ ID NO:91 or a fragment thereof.

37. (Currently Amended) The isolated hyperimmune serum-reactive antigen or fragment of claim 36, further defined as a peptide ~~comprising~~consisting of an amino acid sequence described in: the “predicted immunogenic aa,” “Predicted class II restricted T-Cell epitopes / regions,” “Predicted class I restricted T-Cell epitope / regions,” and/or “location of identified immunogenic region” column of Table 1A or 1C or in Table 2.

38. (Currently Amended) The isolated hyperimmune serum reactive antigen or fragment of claim 36, further defined as ~~comprising~~consisting of an amino acid sequence of amino acid 4-10, 16-28, 3-14, 16-30 and 2-16 of SEQ ID NO:91 and fragments in 9 amino acid length starting from the position of 1 and 15 of SEQ ID NO:91.

39. (Currently Amended) The isolated hyperimmune serum-reactive antigen or fragment of claim 36, comprising at least 6 contiguous amino acids of SEQ ID NO:91.

40. (Currently Amended) The isolated hyperimmune serum-reactive antigen or fragment of claim 36, comprising at least 8 contiguous amino acids of SEQ ID NO:91.

41. (Currently Amended) The isolated hyperimmune serum-reactive antigen or fragment of claim 36, comprising at least 10 contiguous amino acids of SEQ ID NO:91.

42. (Canceled)

43. (Currently Amended) A pharmaceutical composition comprising an isolated hyperimmune serum-reactive antigen or fragment of claim 36.

44. (Canceled)

45. (Previously Presented) The pharmaceutical composition of claim 43, further defined as comprising at least two different hyperimmune serum-reactive antigens and/or fragments.
46. (Canceled)
47. (Previously Presented) The pharmaceutical composition of claim 43, further comprising an immunostimulatory substance.
48. (Previously Presented) The pharmaceutical composition of claim 47, wherein the immunostimulatory substance is a polycationic polymer, an immunostimulatory deoxynucleotide (ODN), a peptide containing at least two LysLeuLys motifs, a neuroactive compound, alum, or a Freund's complete or incomplete adjuvant.
49. (Previously Presented) The pharmaceutical composition of claim 48, wherein the polycationic polymer is a polycationic peptide.
50. (Previously Presented) The pharmaceutical composition of claim 48, wherein the neuroactive compound is human growth hormone.
51. (Previously Presented) The pharmaceutical composition of claim 43, further defined as a vaccine.
52. (Canceled)
53. (Withdrawn) A method of vaccinating a subject comprising:
obtaining a pharmaceutical composition of claim 43; and
administering the pharmaceutical composition to a subject;
wherein the subject is vaccinated.
54. (Withdrawn) The method of claim 53, wherein the subject is a human.
55. (Withdrawn) The method of claim 53, further defined as a method of treating and/or preventing *C. pneumoniae* infection in the subject.
56. (Withdrawn) The method of claim 53, wherein the hyperimmune serum-reactive antigen or fragment is directed against *C. pneumoniae*.